Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

QNTM Quantum Biopharma Ltd

4,6791

-0,2609 (-5,28%)

01 Mär 2025 - Geschlossen

Verzögert um 15 Minuten

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

nullnull

Quantum Biopharma (NASDAQ:QNTM)
Historical Stock Chart
Von Feb 2025 bis Mär 2025

Click Here for more Quantum Biopharma Charts.

Quantum Biopharma (NASDAQ:QNTM)
Historical Stock Chart
Von Mär 2024 bis Mär 2025

Click Here for more Quantum Biopharma Charts.

News Quantum Biopharma Ltd

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mittwoch 26 Februar 2025 (4 Tage vor) • Edgar (US Regulatory)

Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302
Mittwoch 26 Februar 2025 (4 Tage vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Dienstag 18 Februar 2025 (2 Wochen vor) • Edgar (US Regulatory)

Quantum BioPharma Continues to Diversify its Treasury with the Purchase of Another USD $1,000,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies
Dienstag 18 Februar 2025 (2 Wochen vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Dienstag 11 Februar 2025 (3 Wochen vor) • Edgar (US Regulatory)

Quantum Biopharma Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
Dienstag 11 Februar 2025 (3 Wochen vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Montag 10 Februar 2025 (3 Wochen vor) • Edgar (US Regulatory)

Quantum Biopharma Engages Enterprise Canada and Empire Market Ventures to Lead Public Communications and Investor Awareness Programs
Montag 10 Februar 2025 (3 Wochen vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Donnerstag 6 Februar 2025 (3 Wochen vor) • Edgar (US Regulatory)

Quantum Biopharma Licensee Celly Nutrition Retains Leading New York Investment Bank to Advise on Capital Raise and Possible Initial Public Offering Following Highly Positive Results from unbuzzd™ Clinical Study
Donnerstag 6 Februar 2025 (3 Wochen vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Dienstag 4 Februar 2025 (4 Wochen vor) • Edgar (US Regulatory)

Quantum Biopharma Announces the Success of unbuzzd™ Clinical Trial
Dienstag 4 Februar 2025 (4 Wochen vor) • GlobeNewswire Inc.

Weitere Quantum Biopharma Ltd News-Artikel

Ultragenyx Pharmaceutical

Societe Generale Effekten

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen